Recent News

• 01.15.2026 - Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
• 01.15.2026 - Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
• 01.08.2026 - Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
• 01.08.2026 - Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
• 11.13.2025 - Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.13.2025 - Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.07.2025 - Vaxart to Host Upcoming Conference Calls
• 11.07.2025 - Vaxart to Host Upcoming Conference Calls
• 11.05.2025 - Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

Recent Filings

• 12.29.2025 - 8-K Current report
• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 144 Report of proposed sale of securities
• 12.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - EX-99.1 EX-99.1